<DOC>
	<DOCNO>NCT01021943</DOCNO>
	<brief_summary>The main objective study assess effect spironolactone interstitial fibrosis kidney transplant recipient receive calcineurin inhibitor</brief_summary>
	<brief_title>Spironolactone Prevention Calcineurin Inhibitor Toxicity Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Kidney Failure Age &gt; 18 Kidney transplant recipient Patients take angiotensin receptor blocker inhibitor angiotensin reconvert enzyme Kidney transplant perform one month enrollment study Hyperkalemia ( K &gt; 5.5 meqL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>fibrosis</keyword>
	<keyword>spironolactone</keyword>
	<keyword>Focus study ass aldosterone blockade effect interstitial fibrosis amongst kidney transplant recipient</keyword>
</DOC>